|
1
|
Kipps E, Tan DS and Kaye SB: Meeting the
challenge of ascites in ovarian cancer: New avenues for therapy and
research. Nat Rev Cancer. 13:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baguley BC: Multidrug resistance in
cancer. Methods Mol Biol. 596:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mechetner EB and Roninson IB: Efficient
inhibition of P-glycoprotein-mediated multidrug resistance with a
monoclonal antibody. Proc Natl Acad Sci USA. 89:5824–5828. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Breier A, Gibalova L, Seres M, Barancik M
and Sulova Z: New insight into p-glycoprotein as a drug target.
Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gibalová L, Sereš M, Rusnák A, Ditte P,
Labudová M, Uhrík B, Pastorek J, Sedlák J, Breier A and Sulová Z:
P-glycoprotein depresses cisplatin sensitivity in L1210 cells by
inhibiting cisplatin-induced caspase-3 activation. Toxicol In
Vitro. 26:435–444. 2012. View Article : Google Scholar
|
|
7
|
Hellström I, Raycraft J, Hayden-Ledbetter
M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N and
Hellström KE: The HE4 (WFDC2) protein is a biomarker for ovarian
carcinoma. Cancer Res. 63:3695–3700. 2003.
|
|
8
|
Aarenstrup Karlsen M, Høgdall C,
Nedergaard L, Philipsen Prahm K, Schou Karlsen NM, Weng Ekmann-Gade
A, Henrichsen Schnack T, Svenstrup Poulsen T, Jarle Christensen I
and Høgdall E: HE4 as a predictor of adjuvant chemotherapy
resistance and survival in patients with epithelial ovarian cancer.
APMIS. 124:1038–1045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nassir M, Guan J, Luketina H, Siepmann T,
Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van
Nieuwenhuysen E, et al: The role of HE4 for prediction of
recurrence in epithelial ovarian cancer patients-results from the
OVCAD study. Tumour Biol. 37:3009–3016. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ribeiro JR, Schorl C, Yano N, Romano N,
Kim KK, Singh RK and Moore RG: HE4 promotes collateral resistance
to cisplatin and paclitaxel in ovarian cancer cells. J Ovarian Res.
9:282016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanaka T, Akatsuka S, Ozeki M, Shirase T,
Hiai H and Toyokuni S: Redox regulation of Annexin II and its
implications for oxidative stress-induced renal carcinogenesis and
metastasis. Oncogene. 23:3980–3989. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bjørnland K, Winberg JO, Odegaard OT,
Hovig E, Loennechen T, Aasen AO, Fodstad O and Maelandsmo GM:
S100A4 involvement in metastasis: Deregulation of matrix
metalloproteinases and tissue inhibitors of matrix
metalloproteinases in osteosarcoma cells transfected with an
anti-S100A4 ribozyme. Cancer Res. 59:4702–4708. 1999.
|
|
13
|
Mathisen B, Lindstad RI, Hansen J,
El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T and
Winberg JO: S100A4 regulates membrane induced activation of matrix
metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis.
20:701–711. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao
J, Zhu L and Lin B: Human epididymis protein 4 in association with
Annexin II promotes invasion and metastasis of ovarian cancer
cells. Mol Cancer. 13:2432014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji
W, Yang Y and Niu R: P-glycoprotein associates with Anxa2 and
promotes invasion in multidrug resistant breast cancer cells.
Biochem Pharmacol. 87:292–302. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang ZD, Li Y, Fan Q, Zhao B, Tan B and
Zhao XF: Annexin II is implicated in multi-drug-resistance in
gastric cancer through p38MAPK and AKT pathway. Neoplasma.
61:627–637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li N, Yang L, Wang H, Yi T, Jia X, Chen C
and Xu P: MiR-130a and MiR-374a function as novel regulators of
cisplatin resistance in human ovarian cancer A2780 Cells. PLoS One.
10:e01288862015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jung H, Kim JS, Kim WK, Oh KJ, Kim JM, Lee
HJ, Han BS, Kim DS, Seo YS, Lee SC, et al: Intracellular Annexin II
regulates NF-κB signaling by binding to the p50 subunit:
Implications for gemcitabine resistance in pancreatic cancer. Cell
Death Dis. 6:e16062015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang R, Lu M, Zhang Z, Tian X, Wang S and
Lv D: Resveratrol reverses P-glycoprotein-mediated multidrug
resistance of U2OS/ADR cells by suppressing the activation of the
NF-κB and p38 MAPK signaling pathways. Oncol Lett. 12:4147–4154.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
FIGO Committee on Gynecologic Oncology, .
Current FIGO staging for cancer of the vagina, fallopian tube,
ovary, and gestational trophoblastic neoplasia. Int J Gynaecol
Obstet. 105:3–4. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morgan RJ Jr, Copeland L, Gershenson D,
Locker G, McIntosh D, Ozols R and Teng N; The National
Comprehensive Cancer Network, : NCCN ovarian cancer practice
guidelines. Oncology (Williston Park). 10 (Suppl 11):293–310.
1996.PubMed/NCBI
|
|
22
|
Zhuang H, Gao J, Hu Z, Liu J, Liu D and
Lin B: Co-expression of Lewis y antigen with human epididymis
protein 4 in ovarian epithelial carcinoma. PLoS One. 8:e689942013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang H, Tan M, Zhang S, Li X, Gao J, Zhang
D, Hao Y, Gao S, Liu J and Lin B: Expression and significance of
CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol
Sci. 16:3391–3404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moore RG, Hill EK, Horan T, Yano N, Kim K,
MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller
MC, et al: HE4 (WFDC2) gene overexpression promotes ovarian tumor
growth. Sci Rep. 4:35742014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Armstrong DK, Alvarez RD, Bakkum-Gamez JN,
Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M,
DeRosa M, et al: NCCN guidelines insights: Ovarian cancer, Version
1. J Natl Compr Canc Netw. 17:896–909. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim VN and Nam JW: Genomics of microRNA.
Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y
and Fan D: Methylation of miR-129-5p CpG island modulates
multi-drug resistance in gastric cancer by targeting ABC
transporters. Oncotarget. 5:11552–11563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Islam SU, Shehzad A, Sonn JK and Lee YS:
PRPF overexpression induces drug resistance through actin
cytoskeleton rearrangement and epithelial-mesenchymal transition.
Oncotarget. 8:56659–56671. 2017. View Article : Google Scholar : PubMed/NCBI
|
